Due to its high expression on myeloma cells monoclonal antibodies have been developed to target SLAMF7 as a tumor antigen, leading to NK-cell mediated antibody-dependent cellular cytotoxicity (ADCC) (17–19). This evidence concerns the gene SLAMF7 and neoplasm.